Neven P - Search Results

1

Prophylactic salpingo-oophorectomy in 51 women with familial breast-ovarian cancer: importance of fallopian tube dysplasia.

Leunen K, Legius E, Moerman P, Amant F, Neven P, Vergote I. Leunen K, et al. Among authors: neven p. Int J Gynecol Cancer. 2006 Jan-Feb;16(1):183-8. doi: 10.1111/j.1525-1438.2006.00287.x. Int J Gynecol Cancer. 2006. PMID: 16445631

2

A realistic clinical perspective of tamoxifen and endometrial carcinogenesis.

Assikis VJ, Neven P, Jordan VC, Vergote I. Assikis VJ, et al. Among authors: neven p. Eur J Cancer. 1996 Aug;32A(9):1464-76. doi: 10.1016/0959-8049(96)00184-0. Eur J Cancer. 1996. PMID: 8911103 Review.

3

Should tamoxifen users be screened for endometrial lesions?

Neven P, Vergote I. Neven P, et al. Lancet. 1998 Jan 17;351(9097):155-7. doi: 10.1016/S0140-6736(05)78216-7. Lancet. 1998. PMID: 9449866 No abstract available.

4

Controversies regarding tamoxifen and uterine carcinoma.

Neven P, Vergote I. Neven P, et al. Curr Opin Obstet Gynecol. 1998 Feb;10(1):9-14. doi: 10.1097/00001703-199802000-00003. Curr Opin Obstet Gynecol. 1998. PMID: 9484623 Review.

5

Genomic changes in endometrial polyps associated with tamoxifen show no evidence for its action as an external carcinogen.

Dal Cin P, Timmerman D, Van den Berghe I, Wanschura S, Kazmierczak B, Vergote I, Deprest J, Neven P, Moerman P, Bullerdiek J, Van den Berghe H. Dal Cin P, et al. Among authors: neven p. Cancer Res. 1998 Jun 1;58(11):2278-81. Cancer Res. 1998. PMID: 9622058

6

The oestrogen receptor and its selective modulators in gynaecological and breast cancer.

Vergote I, Neven P, van Dam P, Serreyn R, De Prins F, De Sutter P, Albertyn G. Vergote I, et al. Among authors: neven p. Eur J Cancer. 2000 Sep;36 Suppl 4:S1-9. doi: 10.1016/s0959-8049(00)00203-3. Eur J Cancer. 2000. PMID: 11056296 No abstract available.

7

Tamoxifen, screening and new oestrogen receptor modulators.

Neven P, Vergote I. Neven P, et al. Best Pract Res Clin Obstet Gynaecol. 2001 Jun;15(3):365-80. doi: 10.1053/beog.2001.0182. Best Pract Res Clin Obstet Gynaecol. 2001. PMID: 11476559 Review.

8

Endocrine treatment and prevention of breast and gynaecological cancers.

Neven P, Vergote I, Van Ginderachter J, van Dam P, Tjalma W, De Rop C, De Prins F. Neven P, et al. Eur J Cancer. 2002 Nov;38 Suppl 6:S1-11. doi: 10.1016/s0959-8049(02)00267-8. Eur J Cancer. 2002. PMID: 12409056 No abstract available.

9

Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients.

Morales L, Timmerman D, Neven P, Konstantinovic ML, Carbonez A, Van Huffel S, Ameye L, Weltens C, Christiaens MR, Vergote I, Paridaens R. Morales L, et al. Among authors: neven p. Ann Oncol. 2005 Jan;16(1):70-4. doi: 10.1093/annonc/mdi021. Ann Oncol. 2005. PMID: 15598941 Free article. Clinical Trial.

10

Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer.

Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, Berteloot P, Amant F, Vergote I, Christiaens MR. Huang HJ, et al. Among authors: neven p. J Clin Pathol. 2005 Jun;58(6):611-6. doi: 10.1136/jcp.2004.022772. J Clin Pathol. 2005. PMID: 15917412 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

559 results

Search Page

Filters